Stockscreener 앱 받기
1.76
1.73%
0.03
시장 영업 전:
1.81
0.05
+2.84%
Annovis Bio Inc 주식(ANVS)의 최신 뉴스
Annovis Bio Price Target Maintained With a $17.00/Share by Canaccord Genuity - Moomoo
Aug Summary: Will Annovis Bio Inc stock recover after earnings2026 Chart Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn
Malvern company closes $10M offering to extend Alzheimer’s therapy testing - Pennsylvania Business Report -
Fed Watch: Can Annovis Bio Inc disrupt its industry2026 Spike Watch & Safe Capital Preservation Plans - baoquankhu1.vn
Retail Trends: Will Annovis Bio Inc benefit from seasonalityPortfolio Growth Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Annovis Bio highlights buntanetap development in published article - MSN
Annovis secures financing for buntanetap’s NDA submission - The Pharma Letter
Annovis Bio raises $10M to fund Alzheimer’s drug trial - Investing.com
Annovis Bio raises $10M to fund Alzheimer’s drug trial By Investing.com - Investing.com UK
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission - ChartMill
Annovis Bio Announces $10 Million Underwritten Offering to Advance Alzheimer’s and Parkinson’s Drug Development - Minichart
Annovis Bio Prices Registered Direct Offering to Fund Trials - TipRanks
Annovis Bio (ANVS) price target increased by 13.94% to 15.98 - MSN
Annovis Bio Secures ~$10 Million Underwritten Registered Direct Offering With Canaccord Genuity - TradingView — Track All Markets
Weekly Trades: Will Annovis Bio Inc. benefit from rising consumer demand2026 Market Trends & Safe Capital Preservation Plans - baoquankhu1.vn
Quarterly Risk: Will Annovis Bio Inc stock hit new highs in YEAR2026 Growth vs Value & Weekly Breakout Watchlists - baoquankhu1.vn
Annovis Bio prices $10M stock offering at $1.90 per share - Investing.com Australia
Annovis Bio (ANVS) launches $10M stock and warrant offering for Phase 3 drug - Stock Titan
Annovis Bio (ANVS) raises ~$10M via 5.26M-share registered direct offering - Stock Titan
Form 424B5 Annovis Bio, Inc. - StreetInsider
Annovis Bio stock tumbles 26% on dilutive equity offering By Investing.com - Investing.com India
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Annovis Bio stock tumbles 26% on dilutive equity offering - Investing.com
Anovis Bio Inc stock: $10M raise amid Phase 3 push – what it means for you - AD HOC NEWS
Annovis announces $10 million underwritten offering of common stock and accompanying warrants - marketscreener.com
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants - The Manila Times
ANVS Earnings History & Surprises | EPS & Revenue Results | ANNOVIS BIO (NYSE:ANVS) - ChartMill
Annovis Secures U.S. Patent for Buntanetap Neurological Use - MyChesCo
Annovis Bio Highlights Buntanetap Development in Published Article - MyChesCo
Will Annovis Bio Inc benefit from government policyEarnings Trend Report & Low Risk High Win Rate Picks - baoquankhu1.vn
Options Flow: Can Annovis Bio Inc deliver consistent dividendsChart Signals & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Growth Value: Whats the analyst consensus on Annovis Bio IncMarket Movers & Verified Chart Pattern Signals - baoquankhu1.vn
Annovis Strengthens Patent Portfolio With Buntanetap, Stock Up - RTTNews
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
ANVS.N Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Insider Buying: Annovis Bio (NYSE:ANVS) Director Acquires 713,800 Shares of Stock - MarketBeat
Annovis Bio Director Purchased Shares Worth Over $1.4M - TradingView — Track All Markets
Director Michael Hoffman buys 713,800 Annovis Bio (ANVS) shares in open market - Stock Titan
Annovis Bio receives patent for buntanetap in brain infections By Investing.com - Investing.com Australia
[144] Annovis Bio, Inc. SEC Filing - Stock Titan
Annovis Bio, Inc. Secures Patent for Buntanetap in Prevention and Treatment of Neurological Injuries from Infectious Agents - Quiver Quantitative
Annovis Bio receives patent for buntanetap in brain infections - Investing.com
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections - The Manila Times
Annovis Secures U.S. Patent for Buntanetap in the - GlobeNewswire
ANVS Stock Price and Chart — NYSE:ANVS - TradingView
ANVS.N PE Ratio & Valuation, Is ANVS.N Overvalued - Intellectia AI
Annovis Publishes Historical Review of Buntanetap in The Scientist - Bitget
Bearish Setup: Will Annovis Bio Inc stock hit new highs in YEAR2026 Technicals & Growth-Oriented Investment Plans - baoquankhu1.vn
2.69%
0.25%
자본화:
|
볼륨(24시간):